Therapeutic proteins

Methods in Molecular Biology

Volumn 899, Issue , 2012, Pages 1-26

  Dimitrov, Dimiter S ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Antibodies; Cancer; Efficacy; Immune diseases; Immunogenicity; Proteins; Safety; Therapeutics; Vaccines

Indexed keywords

ANTITHROMBIN III; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; MONOCLONAL ANTIBODY;

ARTICLE; CLASSIFICATION; ECONOMICS; EUROPEAN UNION; HUMAN; IMMUNOPATHOLOGY; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; PROTEIN ENGINEERING; UNITED STATES;

ANTIBODIES, MONOCLONAL; ANTITHROMBIN III; EUROPEAN UNION; HUMANS; IMMUNE SYSTEM DISEASES; IMMUNOGLOBULIN FC FRAGMENTS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN ENGINEERING; RECOMBINANT FUSION PROTEINS; UNITED STATES;

EID: 84864148041     PISSN: 10643745     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-61779-921-1_1     Document Type: Article

References (65)

1. Carter PJ (2006) Potent antibody therapeutics by design. Nat Rev Immunol 6:343-357
2. Schrama D, Reisfeld RA, Becker JC (2006) Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 5:147-159
3. Waldmann TA (2003) Immunotherapy: Past, present and future. Nat Med 9:269-277
4. Casadevall A, Dadachova E, Pirofski LA (2004) Passive antibody therapy for infectious diseases. Nat Rev Microbiol 2:695-703
5. Carter PJ (2011) Introduction to current and future protein therapeutics: A protein engineering perspective. Exp Cell Res 317: 1261-1269
6. Dimitrov DS (2010) Therapeutic antibodies, vaccines and antibodyomes. MAbs 2:347-356
7. Walsh G (2010) Biopharmaceutical benchmarks 2010. Nat Biotechnol 28:917-924
8. Leader B, Baca QJ, Golan DE (2008) Protein therapeutics: A summary and pharmacological classi fi cation. Nat Rev Drug Discov 7:21-39
9. Dimitrov DS, Marks JD (2009) Therapeutic antibodies: Current state and future trends-is a paradigm change coming soon? Methods Mol Biol 525:1-27
10. Ashkenazi A (2008) Directing cancer cells to self-destruct with pro-Apoptotic receptor agonists. Nat Rev Drug Discov 7:1001-1012
11. Beck A, Reichert JM (2011) Therapeutic Fc-fusion proteins and peptides as successful alternatives to antibodies. MAbs 3(5):415-416
12. Reichert JM (2011) Antibody-based therapeutics to watch in 2011. MAbs 3:76-99
13. Reichert JM (2010) Metrics for antibody therapeutics development. MAbs 2:695-700
14. Kohler G, Milstein C (1975) Continuous cultures of fused cells secreting antibody of prede fi ned specificity. Nature 256:495-497
15. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci USA 76:106-110
16. Feng Y, Dimitrov DS (2008) Monoclonal antibodies against components of the IGF system for cancer treatment. Curr Opin Drug Discov Devel 11:178-185
17. Wu H, Pfarr DS, Tang Y, An LL, Patel NK, Watkins JD, Huse WD, Kiener PA, Young JF (2005) Ultra-potent antibodies against respiratory syncytial virus: Effects of binding kinetics and binding valence on viral neutralization. J Mol Biol 350:126-144
18. Skerra A (2007) Alternative non-Antibody scaffolds for molecular recognition. Curr Opin Biotechnol 18:295-304
19. Chen W, Dimitrov DS (2009) Human monoclonal antibodies and engineered antibody domains as HIV-1 entry inhibitors. Curr Opin HIV AIDS 4:112-117
20. Chen W, Zhu Z, Feng Y, Xiao X, Dimitrov DS (2008) Construction of a large phage-displayed human antibody domain library with a scaffold based on a newly identi fi ed highly soluble, stable heavy chain variable domain. J Mol Biol 382:779-789
21. Chen W, Zhu Z, Feng Y, Dimitrov DS (2008) Human domain antibodies to conserved sterically restricted regions on gp120 as exceptionally potent cross-reactive HIV-1 neutralizers. Proc Natl Acad Sci USA 105:17121-17126
22. Chen W, Xiao X, Wang Y, Zhu Z, Dimitrov DS (2010) Bifunctional fusion proteins of the human engineered antibody domain m36 with human soluble CD4 are potent inhibitors of diverse HIV-1 isolates. Antiviral Res 88: 107-115
23. Dimitrov DS (2009) Engineered CH2 domains (nanoantibodies). MAbs 1:26-28
24. Xiao X, Feng Y, Vu BK, Ishima R, Dimitrov DS (2009) A large library based on a novel (CH2) scaffold: Identi fi cation of HIV-1 inhibitors. Biochem Biophys Res Commun 387: 387-392
25. Gong R, Vu BK, Feng Y, Prieto DA, Dyba MA, Walsh JD, Prabakaran P, Veenstra TD, Tarasov SG, Ishima R, Dimitrov DS (2009) Engineered human antibody constant domains with increased stability. J Biol Chem 284: 14203-14210
26. Gong R, Wang Y, Feng Y, Zhao Q, Dimitrov DS (2011) Shortened engineered human antibody CH2 domains: Increased stability and binding to the human neonatal receptor. J Biol Chem 286(3):27288-27293
27. Jiang XR, Song A, Bergelson S, Arroll T, Parekh B, May K, Chung S, Strouse R, Mire-Sluis A, Schenerman M (2011) Advances in the assessment and control of the effector functions of therapeutic antibodies. Nat Rev Drug Discov 10:101-111
28. Descotes J, Gouraud A (2008) Clinical immunotoxicity of therapeutic proteins. Expert Opin Drug Metab Toxicol 4:1537-1549
29. Suntharalingam G, Perry MR, Ward S, Brett SJ, Castello-Cortes A, Brunner MD, Panoskaltsis N (2006) Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 355: 1018-1028
30. Ewer SM, Ewer MS (2008) Cardiotoxicity pro fi le of trastuzumab. Drug Saf 31:459-467
31. Chung CH (2008) Managing premedications and the risk for reactions to infusional monoclonal antibody therapy. Oncologist 13:725-732
32. Winter MC, Hancock BW (2009) Ten years of rituximab in NHL. Expert Opin Drug Saf 8:223-235
33. Pendley C, Schantz A, Wagner C (2003) Immunogenicity of therapeutic monoclonal antibodies. Curr Opin Mol Ther 5:172-179
34. Schellekens H (2008) How to predict and prevent the immunogenicity of therapeutic proteins. Biotechnol Annu Rev 14:191-202
35. Onda M (2009) Reducing the immunogenicity of protein therapeutics. Curr Drug Targets 10:131-139
36. Baker MP, Jones TD (2007) Identi fi cation and removal of immunogenicity in therapeutic proteins. Curr Opin Drug Discov Devel 10:219-227
37. Stas P, Lasters I (2009) Strategies for preclinical immunogenicity assessment of protein therapeutics. IDrugs 12:169-173
38. De Groot AS, McMurry J, Moise L (2008) Prediction of immunogenicity: In silico paradigms, ex vivo and in vivo correlates. Curr Opin Pharmacol 8:620-626
39. Emi AN, de Carvalho JF, Artur Almeida SC, Bonfa E (2010) Immunogenicity of Anti-TNFalpha agents in autoimmune diseases. Clin Rev Allergy Immunol 38(2-3):82-89
40. Hangartner L, Zinkernagel RM, Hengartner H (2006) Antiviral antibody responses: The two extremes of a wide spectrum. Nat Rev Immunol 6:231-243
41. Dixit R, Coats S (2009) Preclinical ef fi cacy and safety models for mAbs: The challenge of developing effective model systems. IDrugs 12:103-108
42. Castillo J, Winer E, Quesenberry P (2008) Newer monoclonal antibodies for hematological malignancies. Exp Hematol 36:755-768
43. Mariani G, Fasolo A, De BE, Gianni L (2009) Trastuzumab as adjuvant systemic therapy for HER2-positive breast cancer. Nat Clin Pract Oncol 6:93-104
44. Bedard PL, Piccart-Gebhart MJ (2008) Current paradigms for the use of HER2-targeted therapy in early-stage breast cancer. Clin Breast Cancer 8(Suppl 4):S157-S165
45. Hall PS, Cameron DA (2009) Current perspective- trastuzumab. Eur J Cancer 45:12-18
46. Cameron D, Casey M, Press M, Lindquist D, Pienkowski T, Romieu CG, Chan S, Jagiello- Gruszfeld A, Kaufman B, Crown J, Chan A, Campone M, Viens P, Davidson N, Gorbounova V, Raats JI, Skarlos D, Newstat B, Roychowdhury D, Paoletti P, Oliva C, Rubin S, Stein S, Geyer CE (2008) A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: Updated ef fi cacy and biomarker analyses. Breast Cancer Res Treat 112:533-543
47. Norden AD, Drappatz J, Wen PY (2008) Novel anti-Angiogenic therapies for malignant gliomas. Lancet Neurol 7:1152-1160
48. Sachdev JC, Jahanzeb M (2008) Evolution of bevacizumab-based therapy in the management of breast cancer. Clin Breast Cancer 8: 402-410
49. Patel DK (2008) Clinical use of anti-Epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer. Pharmacotherapy 28:31S-41S
50. Tassev DV, Cheung NK (2009) Monoclonal antibody therapies for solid tumors. Expert Opin Biol Ther 9:341-353
51. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I (2009) Mechanisms of tumor resistance to EGFRtargeted therapies. Expert Opin Ther Targets 13:339-362
52. Presta LG (2008) Molecular engineering and design of therapeutic antibodies. Curr Opin Immunol 20:460-470
53. Jefferis R (2009) Glycosylation as a strategy to improve antibody-based therapeutics. Nat Rev Drug Discov 8:226-234
54. Labrijn AF, Aalberse RC, Schuurman J (2008) When binding is enough: Nonactivating antibody formats. Curr Opin Immunol 20: 479-485
55. Kiewe P, Thiel E (2008) Ertumaxomab: A trifunctional antibody for breast cancer treatment. Expert Opin Investig Drugs 17:1553-1558
56. Weber J (2009) Ipilimumab: Controversies in its development, utility and autoimmune adverse events. Cancer Immunol Immunother 58:823-830
57. Yuan J, Gnjatic S, Li H, Powel S, Gallardo HF, Ritter E, Ku GY, Jungbluth AA, Segal NH, Rasalan TS, Manukian G, Xu Y, Roman RA, Terzulli SL, Heywood M, Pogoriler E, Ritter G, Old LJ, Allison JP, Wolchok JD (2008) CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical bene fi t. Proc Natl Acad Sci USA 105:20410-20415
58. Bellail AC, Qi L, Mulligan P, Chhabra V, Hao C (2009) TRAIL agonists on clinical trials for cancer therapy: The promises and the challenges. Rev Recent Clin Trials 4:34-41
59. Feng Y, Xiao X, Zhu Z, Dimitrov DS (2010) Identi fi cation and characterization of a novel agonistic anti-DR4 human monoclonal antibody. MAbs 2:565-570
60. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, Choudhary A, Feng YR, Sanz I, Rybak S, Broder CC, Quinnan GV, Evans T, Dimitrov DS (2003) Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 283:17-25
61. Choudhry V, Zhang MY, Sidorov IA, Louis JM, Harris I, Dimitrov AS, Bouma P, Cham F, Choudhary A, Rybak SM, Fouts T, Monte fi ori DC, Broder CC, Quinnan GV Jr, Dimitrov DS (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly HIV-1 neutralizing antibodies. Virology 363:79-90
62. Zhang MY, Dimitrov DS (2007) Novel approaches for identi fi cation of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency. Curr Pharm Des 13:203-212
63. Liu H, Gaza-Bulseco G, Faldu D, Chumsae C, Sun J (2008) Heterogeneity of monoclonal antibodies. J Pharm Sci 97:2426-2447
64. Birch JR, Racher AJ (2006) Antibody production. Adv Drug Deliv Rev 58:671-685
65. Zhou JX, Tressel T, Yang X, Seewoester T (2008) Implementation of advanced technologies in commercial monoclonal antibody production. Biotechnol J 3:1185-1200